Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Weng

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
BJUI Compass|December 22, 2025
Long non-coding RNAs define favourable biology in high-risk non-muscle-invasive bladder cancerRachel Weng, Tran Anh Thu Phung, Robert Bell, et al.
European Urology Oncology|February 28, 2026
A Long Noncoding RNA-based Classifier for Identifying More Aggressive Low-grade Ta Bladder Cancer with Elevated FGFR3 ActivityTran Anh Thu Phung, Rachel Weng, Peter C Black, et al.
The Journal of Allergy and Clinical Immunology|September 6, 2025
Anifrolumab treatment of Singleton-Merten syndrome 2 due to a novel RIGI variantEvan E Hsu, Courtney E LeSon, Michael T Lam, et al.
The Journal of Allergy and Clinical Immunology|December 2, 2024
Features of hyperinflammation link the biology of Epstein-Barr virus infection and cytokine storm syndromesMeng Liu, Kailey E Brodeur, Jacob R Bledsoe, et al.
The Journal of Allergy and Clinical Immunology|February 4, 2026
A clinically validated assay for rapid determination of type I and type II interferon activity in systemic inflammatory diseasesMichael T Lam, Amrita Basu, Kailey E Brodeur, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 28, 2025
Diagnostic Implications and Correlates of Plasma Adenosine Deaminase 2 Activity and ADA2 VariantsJian Yue, Courtney E LeSon, Casey A Rimland, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
BJUI Compass|December 22, 2025
Long non-coding RNAs define favourable biology in high-risk non-muscle-invasive bladder cancerRachel Weng, Tran Anh Thu Phung, Robert Bell, et al.
European Urology Oncology|February 28, 2026
A Long Noncoding RNA-based Classifier for Identifying More Aggressive Low-grade Ta Bladder Cancer with Elevated FGFR3 ActivityTran Anh Thu Phung, Rachel Weng, Peter C Black, et al.
The Journal of Allergy and Clinical Immunology|September 6, 2025
Anifrolumab treatment of Singleton-Merten syndrome 2 due to a novel RIGI variantEvan E Hsu, Courtney E LeSon, Michael T Lam, et al.
The Journal of Allergy and Clinical Immunology|December 2, 2024
Features of hyperinflammation link the biology of Epstein-Barr virus infection and cytokine storm syndromesMeng Liu, Kailey E Brodeur, Jacob R Bledsoe, et al.
The Journal of Allergy and Clinical Immunology|February 4, 2026
A clinically validated assay for rapid determination of type I and type II interferon activity in systemic inflammatory diseasesMichael T Lam, Amrita Basu, Kailey E Brodeur, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 28, 2025
Diagnostic Implications and Correlates of Plasma Adenosine Deaminase 2 Activity and ADA2 VariantsJian Yue, Courtney E LeSon, Casey A Rimland, et al.
Pageof 1